Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Patients to get test results via NHS app

Patients to get test results via NHS app

An investment of £50m has been made to upgrade the NHS app

Millions of patients will now be able to access test results and get appointment reminders on their smartphones as the government tries to position the NHS app as the default mode of communication and steer away from traditional methods like letters.

An investment of £50m has been made to upgrade the NHS app and the health service hopes to save £200m over the next three years.


Around 50 million letters are sent to patients each year by the NHS and a switch to digital communication is expected to improve efficiency.

The Department of Health and Social Care said that people who cannot access the app will receive text messages and then a letter as a last resort.

The department says 270 million messages will be sent through the NHS app this financial year - an increase of 70 million on the previous year.

NHS app services were launched in 2018, and now it is used by 87 per cent of hospitals across England.

Patients will be provided appointment reminders through push notifications and the department hopes this will bring down cases of missed appointments.

Work is also under way to enable the app users to add appointments to their phone calendars and request help from their local GP surgeries.

Over 11 million people in the UK log into the NHS app every month, while almost 20 million have opted to receive healthcare messages from the app.

Last month NHS England had announced that millions of patients would be able to get "Amazon-style" tracking updates on their prescriptions through the app, to check if their medicines are ready to collect or have been despatched for delivery.

Health Secretary Wes Streeting said further investments in the app will provide more convenience to the patients.

However, Prof Phil Banfield, chair of the British Medical Association (BMA) council, warned that a digital-first approach must not discriminate or alienate those who don't have access to smartphones and tablets.

More For You

Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less
Wales ranked worst for second-trimester abortion access in the UK

Each year about 175 women travel from Wales to England for care

Wales ranked worst for second-trimester abortion access in the UK

A leading healthcare charity has revealed that Wales is the worst part of the United Kingdom for allowing surgical abortions for women.

Surgical abortion is the process removing pregnancy from the womb by inducing local anaesthesia, conscious sedation or general anaesthesia.

Keep ReadingShow less
The fund offers £150 per eligible child - for up to three children per household.

The fund offers £150 per eligible child - for up to three children per household.

Charity reopens funding to ease back to school financial pressures for community pharmacists

Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)

The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technician

Keep ReadingShow less
Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less
Amandeep Doll RPS  New Director of England

Amandeep Doll

RPS announces new director of England

Amandeep Doll has been named as the new director for England at the Royal Pharmaceutical Society (RPS).

The role of Director for England drives professional leadership for the pharmacy profession in England, and leads on national policy development and advocacy across England, in partnership with the English Pharmacy Board.

Keep ReadingShow less